(Reuters) – Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition. Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of […]
Health
Pfizer, partner BioNTech say updated COVID shot shows better immune response
Audio By Carbonatix
(Reuters) – Pfizer and partner BioNTech said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the U.S. health regulator.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas)